Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-04-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司独立董事关于第一届董事会2022年第三次会议相关事宜的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding their prior approval opinion on the appointment of the audit firm for the 2022 fiscal year. It references the audit firm and the audit engagement but does not contain the audit report itself or detailed financial data. The document is short (516 characters) and serves as an approval or opinion related to audit matters, not the audit report or annual report itself. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and related audit information excluding full annual reports. FY 2022
2022-04-18 Chinese
圣湘生物科技股份有限公司关于股东减持计划时间区间届满暨减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from 圣湘生物科技股份有限公司 regarding the completion of a shareholder's share reduction plan. It details the shareholder's holdings before and after the reduction, the number of shares reduced, the time period of the reduction, and confirms that the reduction plan has been fully implemented. There is no financial statement or detailed financial analysis present, nor is this a report or presentation. The content fits the definition of a Major Shareholding Notification (MRQ), as it reports changes in significant share ownership levels, specifically a reduction by a shareholder holding more than 5%. The document length is short (1425 characters), and it is not an announcement of a report publication but a substantive notification of shareholding changes.
2022-04-14 Chinese
圣湘生物科技股份有限公司关于自愿披露公司相关检测产品获得欧盟CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of a product obtaining EU CE certification. It details the product registration, usage, and associated risks but does not contain financial statements, management discussion, or regulatory filings related to financial performance. The document is relatively short (1616 characters) and serves as a regulatory announcement about product certification and related risks. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2022-04-13 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding the company's plan to repurchase its own shares through centralized bidding. It includes specifics about the purpose, scale, price, funding source, authorization, risks, and procedures related to the share repurchase. The text repeatedly mentions '回购股份' (share repurchase) and discusses the use of repurchased shares for employee stock ownership plans or equity incentives. It also includes information about the board's approval and compliance with regulatory guidelines. There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a simple announcement of a report publication but a substantive disclosure about a capital action. Therefore, it fits the category of Transaction in Own Shares (POS), which covers share repurchase announcements and reports.
2022-03-23 Chinese
圣湘生物科技股份有限公司关于自愿披露公司相关检测产品获得秘鲁和沙特认证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company's board regarding the voluntary disclosure of the company's products obtaining certification in Peru and Saudi Arabia. It details product registration certificates, product descriptions, and potential impacts on the company. There are no financial statements, no detailed financial performance data, no management discussion of financial results, nor is this a transcript or presentation. The document is a regulatory announcement about product certifications and related risks, not a financial report or meeting material. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-03-22 Chinese
圣湘生物科技股份有限公司关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from 圣湘生物科技股份有限公司 regarding the shareholding status of the top ten shareholders and top ten unrestricted shareholders prior to a share repurchase plan. It references a board meeting resolution approving a share repurchase plan and provides detailed shareholding data. The content focuses on shareholding information related to a share buyback, not on financial results, management changes, or other report types. The document length is short (1575 characters) and it is an announcement about share repurchase and shareholder holdings, which fits the category of Transaction in Own Shares (POS).
2022-03-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.